Principal investigators over-optimistically forecast scientific and operational outcomes for clinical trials von Benjamin, Daniel M, Hey, Spencer P, MacPherson, Amanda, Hachem, Yasmina, Smith, Kara S, Zhang, Sean X, Wong, Sandy, Dolter, Samantha, Mandel, David R, Kimmelman, Jonathan

Volltext

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Datab... von Grosjean, Heidi A I, Dolter, Samantha, Meyers, Daniel E, Ding, Philip Q, Stukalin, Igor, Goutam, Siddhartha, Kong, Shiying, Chu, Quincy, Heng, Daniel Y C, Bebb, D Gwyn, Morris, Don G, Cheung, Winson Y, Pabani, Aliyah

Volltext

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors von Meyers, Daniel E., Pasternak, Meghann, Dolter, Samantha, Grosjean, Heidi A.I., Lim, Chloe A., Stukalin, Igor, Goutam, Siddhartha, Navani, Vishal, Heng, Daniel Y.C., Cheung, Winson Y., Morris, Don G., Pabani, Aliyah

Volltext

Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer von Sarvas, Holly, Carlisle, Benjamin, Dolter, Samantha, Vinarov, Esther, Kimmelman, Jonathan

Volltext

Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell l... von Lim, Chloe, Ghosh, Sunita, Morrison, Hali, Meyers, Daniel E., Stukalin, Igor, Dolter, Samantha, Grosjean, Heidi A.I., Kerba, Marc, Hao, Desiree, Pabani, Aliyah

Volltext

Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors von Meyers, Daniel E., Pasternak, Meghann, Dolter, Samantha, Grosjean, Heidi A.I., Lim, Chloe, Stukalin, Igor, Navani, Vishal, Heng, Daniel Yick Chin, Cheung, Winson Y., Morris, Don G., Pabani, Aliyah

Volltext

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials von Gan, Chun L., Stukalin, Igor, Meyers, Daniel E., Dudani, Shaan, Grosjean, Heidi A.I., Dolter, Samantha, Ewanchuk, Benjamin W., Goutam, Siddhartha, Sander, Michael, Wells, Connor, Pabani, Aliyah, Cheng, Tina, Monzon, Jose, Morris, Don, Basappa, Naveen S., Pal, Sumanta K., Wood, Lori A., Donskov, Frede, Choueiri, Toni K., Heng, Daniel Y.C.

Volltext

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade von Navani, Vishal, Meyers, Daniel E., Ruan, Yibing, Boyne, Devon J., O'Sullivan, Dylan E., Dolter, Samantha, Grosjean, Heidi AI, Stukalin, Igor, Heng, Daniel Y.C., Morris, Don G., Brenner, Darren R., Sangha, Randeep, Cheung, Winson Y., Pabani, Aliyah

Volltext

Principal investigators over-optimistically forecast scientific and operational outcomes for clinical trials von Daniel M Benjamin, Spencer P Hey, Amanda MacPherson, Yasmina Hachem, Kara S Smith, Sean X Zhang, Sandy Wong, Samantha Dolter, David R Mandel, Jonathan Kimmelman

Volltext